Sanofi steps back from radioconjugates
The company quietly discontinues AlphaMedix.
ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
